Xin Wang1,2, Zhibin Zhang1,2, Zhiqi Mao2, Xinguang Yu3,4. 1. School of Medicine, Nankai University, 94 Weijin Road, Naikai District, Tianjin, 300071, China. 2. Department of Neurosurgery, The First Medical Center of Chinese, PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China. 3. School of Medicine, Nankai University, 94 Weijin Road, Naikai District, Tianjin, 300071, China. xinguang_yu301@126.com. 4. Department of Neurosurgery, The First Medical Center of Chinese, PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China. xinguang_yu301@126.com.
Abstract
BACKGROUND: Deep brain stimulation (DBS) is an effective intervention for Meige syndrome, a type of dystonia characterized by blepharospasm, facial, and oromandibular dystonia. This individual patient-level data meta-analysis was to identify the potential outcome predictors, compare the stimulation targets and summarize the efficacy of DBS for Meige syndrome. METHODS: Three electronic databases (PubMed, Web of Science and Embase) were searched with no publication data restriction to identify studies regarding DBS for Meige syndrome. The primary outcome was the improvement in BFMDRS-M score. Pearson's correlation coefficients and a stepwise multivariate regression analysis were used to identify the potential prognostic factors. RESULTS: Twenty-three studies (115 patients, 94 with pallidal stimulation and 21 with subthalamic stimulation) were eligible. Patients showed significant improvement in Burke-Fahn-Marsden Dystonia Rating Scale movement (BFMDRS-M) (21.5 ± 11.0 vs 8.6 ± 6.9, P < 0.001) and disability (BFMDRS-D) (6.4 ± 5.1 vs 2.9 ± 2.4, P < 0.001) scores at the last follow-up visit (31.9 ± 30.7 months), compared with scores at baseline. Preoperative BFMDRS-M and BFMDRS-D scores were positively correlated with the relative changes in BFMDRS-M score at the last follow-up visit. On the stepwise multivariate regression, only the preoperative BFMDRS remained significant in the best predictive model. CONCLUSIONS: Based on the existing evidence, pallidal/subthalamic stimulation is an effective therapy for even the refractory Meige syndrome. Higher preoperative scores probably indicate larger improvement. Stimulation targets or other clinical factors do not constitute the outcome predictive factors.
BACKGROUND: Deep brain stimulation (DBS) is an effective intervention for Meige syndrome, a type of dystonia characterized by blepharospasm, facial, and oromandibular dystonia. This individual patient-level data meta-analysis was to identify the potential outcome predictors, compare the stimulation targets and summarize the efficacy of DBS for Meige syndrome. METHODS: Three electronic databases (PubMed, Web of Science and Embase) were searched with no publication data restriction to identify studies regarding DBS for Meige syndrome. The primary outcome was the improvement in BFMDRS-M score. Pearson's correlation coefficients and a stepwise multivariate regression analysis were used to identify the potential prognostic factors. RESULTS: Twenty-three studies (115 patients, 94 with pallidal stimulation and 21 with subthalamic stimulation) were eligible. Patients showed significant improvement in Burke-Fahn-Marsden Dystonia Rating Scale movement (BFMDRS-M) (21.5 ± 11.0 vs 8.6 ± 6.9, P < 0.001) and disability (BFMDRS-D) (6.4 ± 5.1 vs 2.9 ± 2.4, P < 0.001) scores at the last follow-up visit (31.9 ± 30.7 months), compared with scores at baseline. Preoperative BFMDRS-M and BFMDRS-D scores were positively correlated with the relative changes in BFMDRS-M score at the last follow-up visit. On the stepwise multivariate regression, only the preoperative BFMDRS remained significant in the best predictive model. CONCLUSIONS: Based on the existing evidence, pallidal/subthalamic stimulation is an effective therapy for even the refractory Meige syndrome. Higher preoperative scores probably indicate larger improvement. Stimulation targets or other clinical factors do not constitute the outcome predictive factors.
Authors: Mark K Lyons; Barry D Birch; Renee A Hillman; Orland K Boucher; Virgilio Gerald H Evidente Journal: Neurosurg Focus Date: 2010-08 Impact factor: 4.047
Authors: Jill L Ostrem; Leslie C Markun; Graham A Glass; Caroline A Racine; Monica M Volz; Susan L Heath; Coralie de Hemptinne; Philip A Starr Journal: Parkinsonism Relat Disord Date: 2014-01-05 Impact factor: 4.891
Authors: Matthew D F McInnes; David Moher; Brett D Thombs; Trevor A McGrath; Patrick M Bossuyt; Tammy Clifford; Jérémie F Cohen; Jonathan J Deeks; Constantine Gatsonis; Lotty Hooft; Harriet A Hunt; Christopher J Hyde; Daniël A Korevaar; Mariska M G Leeflang; Petra Macaskill; Johannes B Reitsma; Rachel Rodin; Anne W S Rutjes; Jean-Paul Salameh; Adrienne Stevens; Yemisi Takwoingi; Marcello Tonelli; Laura Weeks; Penny Whiting; Brian H Willis Journal: JAMA Date: 2018-01-23 Impact factor: 56.272
Authors: Johannes C Woehrle; Christian Blahak; Kety Kekelia; Hans-Holger Capelle; Hansjoerg Baezner; Eva Grips; Ralf Weigel; Joachim K Krauss Journal: Stereotact Funct Neurosurg Date: 2009-10-21 Impact factor: 1.875
Authors: F Valldeoriola; I Regidor; A Mínguez-Castellanos; E Lezcano; P García-Ruiz; A Rojo; A Salvador; A Castro; F Grandas; J Kulisevsky; M J Martí; P Martínez-Martín; L Relova; J Rumià; A Cámara; J A Burguera; G Linazasoro; J López de Val; J Obeso; M C Rodríguez-Oroz; E Tolosa Journal: J Neurol Neurosurg Psychiatry Date: 2009-09-10 Impact factor: 10.154
Authors: Virgilio Gerald H Evidente; Pnina Rokhlin; Maris H Evidente; Margaret Lambert; Robin Garrett; Francisco A Ponce Journal: Mov Disord Clin Pract Date: 2021-05-24
Authors: Virgilio Gerald H Evidente; Francisco A Ponce; Maris H Evidente; Margaret Lambert; Robin Garrett Journal: Tremor Other Hyperkinet Mov (N Y) Date: 2021-03-18
Authors: Laura M Scorr; Stewart A Factor; Sahyli Perez Parra; Rachel Kaye; Randal C Paniello; Scott A Norris; Joel S Perlmutter; Tobias Bäumer; Tatiana Usnich; Brian D Berman; Marie Mailly; Emmanuel Roze; Marie Vidailhet; Joseph Jankovic; Mark S LeDoux; Richard Barbano; Florence C F Chang; Victor S C Fung; Sarah Pirio Richardson; Andrew Blitzer; H A Jinnah Journal: Front Neurol Date: 2021-09-16 Impact factor: 4.003